GAS5 and gastric cancer: GAS5 expression is reduced in diverse cancers, including gastric cancer, melanoma, esophageal squamous cell carcinoma, non-small cell lung cancer, ovarian cancer, cervical cancer, gliomas, osteosarcoma, pancreatic cancer, bladder cancer, renal cell carcinoma, papillary thyroid carcinoma, neuroblastoma, endometrial cancer, and hepatocellular carcinoma [13], with only some types of cancer exhibiting inconsistent results [9].